A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Purpose: The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Read MoreOlaparib in People With Malignant Mesothelioma
Purpose: The drug olaparib may stop cancer cells from fixing damage to their DNA. It has been approved to treat certain cancers in people that were born with a mutation in the BRCA gene. It has not been approved for treating mesothelioma. But some people with mesothelioma have mutations in a gene, BAP1 related to BRCA. Researchers want to see if olaparib can work in patients with mutations in this gene. They also want to see if works on mutations in other genes or patients without any mutations. They want to see if olaparib causes mesothelioma tumors to shrink.
Read MoreImmunotherapy – What Side Effects Can You Expect?
As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural defense system by strengthening and…
Read MoreTechniques for Determining a Mesothelioma Diagnosis
If you have been exposed to asbestos and are exhibiting symptoms of mesothelioma including: pain in the side of your chest and lower back, shortness of breath, cough, fever, excessive sweating, fatigue, random weight loss, not being able to swallow, being hoarse, or have face and arm swelling it might be a good idea to…
Read MoreA Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Purpose: A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Read MoreONCOS-102 Update: Mesothelioma Patients Responded after Phase II Clinical Trial
Advancement in mesothelioma treatments over the past decade has been relativity stagnant, according to Targovax – a Norwegian immune-cology company dedicated to the study and research of immunotherapy treatments. However, those suffering from mesothelioma have hope, as continuing phases of clinical trials are showing positive results; the latest being ONCOS-12, an immunotherapy treatment that showed…
Read MoreSafer and Less Intrusive Lung Cancer Test
In order to test for cancer, people have to go through invasive and even risky procedures to remove and biopsy a tumor. With these risky procedures between 75 and 85 percent of people find out that the tumor in question is benign and they went through a terrifying surgery to learn they are healthy. Instead…
Read MoreAerosol Chemotherapy – Targeting Peritoneal Mesothelioma Through Pressurized Medicine
Peritoneal mesothelioma is an incredibly rare form of cancer that affects the peritoneum, or abdominal lining. It is not entirely understood how exposure to asbestos causes this type of cancer, but scientists and researchers theorize that ingested asbestos fibers work themselves into the peritoneal cavity, or if inhaled, are transported through the lymph node system.…
Read MorePhase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Purpose: This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.
Read MoreNew Surgical Technique Could Be Ideal for Patients with Advanced Pleural Mesothelioma
Pleural mesothelioma is a rare and aggressive cancer that has been notoriously difficult to treat. Caused by asbestos exposure, the latency period between the time of initial exposure and disease spans decades and generally by the time the cancer is detected, it is highly advanced. Surgical treatments for those with pleural mesothelioma are generally more…
Read More